[1]
|
Kotecha, D. and Piccini, J.P. (2015) Atrial Fibrillation in Heart Failure: What Should We Do? European Heart Journal, 36, 3250-3257. https://doi.org/10.1093/eurheartj/ehv513
|
[2]
|
Piccini, J.P. and Arps, K. (2022) Sacubitril/Valsartan Therapy for AF and HFpEF: Is the Glass Half Empty or Half Full? JACC: Heart Failure, 10, 347-349. https://doi.org/10.1016/j.jchf.2022.02.010
|
[3]
|
Cunningham, J.W., et al. (2020) Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure with Preserved Ejection Fraction. JACC: Heart Failure, 8, 372-381.
https://doi.org/10.1016/j.jchf.2020.03.002
|
[4]
|
Ariyaratnam, J.P., Lau, D.H., Sanders, P. and Kalman, J.M. (2021) Atrial Fibrillation and Heart Failure: Epidemiology, Pathophysiology, Prognosis, and Management. Cardiac Electro-physiology Clinics, 13, 47-62.
https://doi.org/10.1016/j.ccep.2020.11.004
|
[5]
|
Zafrir, B., et al. (2018) Prognostic Implications of Atrial Fibrilla-tion in Heart Failure with Reduced, Mid-Range, and Preserved Ejection Fraction: A Report from 14 964 Patients in the European Society of Cardiology Heart Failure Long- Term Registry. European Heart Journal, 39, 4277-4284. https://doi.org/10.1093/eurheartj/ehy626
|
[6]
|
Packer, M., Lam, C.S.P., Lund, L.H. and Redfield, M.M. (2020) In-terdependence of Atrial Fibrillation and Heart Failure with a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. Circulation, 141, 4-6. https://doi.org/10.1161/CIRCULATIONAHA.119.042996
|
[7]
|
Kitzman, D.W., et al. (2016) Effect of Caloric Re-striction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients with Heart Failure with Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA, 315, 36-46. https://doi.org/10.1001/jama.2015.17346
|
[8]
|
Fukuta, H., Goto, T., Wakami, K., Kamiya, T. and Ohte, N. (2019) Effects of Exercise Training on Cardiac Function, Exercise Capacity, and Quality of Life in Heart Failure with Preserved Ejection Fraction: A Meta-Analysis of Randomized Controlled Trials. Heart Failure Reviews, 24, 535-547. https://doi.org/10.1007/s10741-019-09774-5
|
[9]
|
McDonagh, T.A., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726. https://doi.org/10.1093/eurheartj/ehab368
|
[10]
|
Hindricks, G., et al. (2021) 2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation Developed in Collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Developed with the Special Contribution of the European Heart Rhythm Association (EHRA) of the Esc. European Heart Journal, 42, 373-498.
https://doi.org/10.1093/eurheartj/ehaa612
|
[11]
|
Llàcer, P., et al. (2019) Digoxin and Prognosis of Heart Failure in Older Patients with Preserved Ejection Fraction: Importance of Heart Rate. Results from an Observational and Multicen-ter Study. European Journal of Internal Medicine, 60, 18-23. https://doi.org/10.1016/j.ejim.2018.10.010
|
[12]
|
Singh, S., et al. (2020) Digoxin Initiation and Outcomes in Patients with Heart Failure (HFrEF and HFpEF) and Atrial Fibrilla-tion. The American Journal of Medicine, 133, 1460-1470. https://doi.org/10.1016/j.amjmed.2020.05.030
|
[13]
|
Goyal, P., et al. (2018) Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: Insights on a Unique Clinical Phenotype from a Nationally-Representative United States Cohort. International Journal of Cardiology, 266, 112-118. https://doi.org/10.1016/j.ijcard.2018.02.007
|
[14]
|
Koldenhof, T., et al. (2022) Rate Control Drugs Differ in the Pre-vention of Progression of Atrial Fibrillation. Europace, 24, 384-389. https://doi.org/10.1093/europace/euab191
|
[15]
|
代利友. 维拉帕米治疗心律失常疗效及安全性研究[J]. 临床合理用药, 2017, 10(7): 35-36.
|
[16]
|
陈玲玲, 侯静秀, 何俊辉, 等. 决奈达隆用于心房颤动导管消融术后空白期疗效的临床研究[J]. 心血管康复学杂志, 2022, 31(3): 305-307.
|
[17]
|
赵子明, 王瑞敏, 毛幼林, 陈丰毅. 抗心律失常药物长时程应用与房颤射频消融术后患者预后的研究[J]. 黑龙江医学, 2022, 46(5): 527-529.
|
[18]
|
Vaduganathan, M., et al. (2022) Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: A Post-Hoc Analysis of the ATHENA Trial. European Journal of Heart Failure, 24, 1094-1101. https://doi.org/10.1002/ejhf.2487
|
[19]
|
Capucci, A., Cipolletta, L., Guerra, F. and Giannini, I. (2018) Emerging Pharmacotherapies for the Treatment of Atrial Fibrillation. Expert Opinion on Emerging Drugs, 23, 25-36. https://doi.org/10.1080/14728214.2018.1446941
|
[20]
|
January, C.T., et al. (2014) 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 130, e199-e267. https://doi.org/10.1161/CIR.0000000000000041
|
[21]
|
Uddin, M.E., et al. (2022) MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia. International Journal of Molecular Sciences, 23, Article No. 8607. https://doi.org/10.3390/ijms23158607
|
[22]
|
Bracey, A., Shatila, W. and Wilson, J. (2018) Bleeding in Patients Re-ceiving Non-Vitamin K Oral Anticoagulants: Clinical Trial Evidence. Therapeutic Advances in Cardiovascular Disease, 12, 361-380.
https://doi.org/10.1177/1753944718801554
|
[23]
|
Brown, L.A.E. and Boos, C.J. (2017) Atrial Fibrillation and Heart Failure: Factors Influencing the Choice of Oral Anticoagulant. International Journal of Cardiology, 227, 863-868. https://doi.org/10.1016/j.ijcard.2016.09.086
|
[24]
|
Lund, L.H., Claggett, B., Liu, J., Lam, C.S., Jhund, P.S., Rosano, G.M., Swedberg, K., Yusuf, S., Granger, C.B., Pfeffer, M.A., McMurray, J.J.V. and Solomon, S.D. (2018) Heart Fail-ure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the En-tire Ejection Fraction Spectrum. European Journal of Heart Failure, 20, 1230-1239. https://doi.org/10.1002/ejhf.1149
|
[25]
|
Kiuchi, S., et al. (2017) Azelnidipine Is a Useful Medication for the Treat-ment of Heart Failure Preserved Ejection Fraction. Clinical and Experimental Hypertension, 39, 350-354. https://doi.org/10.1080/10641963.2016.1267198
|
[26]
|
Shantsila, E., et al. (2020) Spironolactone in Atrial Fibrilla-tion with Preserved Cardiac Fraction: The IMPRESS-AF Trial. Journal of the American Heart Association, 9, e016239. https://doi.org/10.1161/JAHA.119.016239
|
[27]
|
Mujadzic, H., Prousi, G.S., Napier, R., Siddique, S. and Zaman, N. (2022) The Impact of Angiotensin Receptor-Ne- prilysin Inhibitors on Arrhythmias in Patients with Heart Failure: A Systematic Review and Meta-Analysis. The Journal of Innovations in Cardiac Rhythm Management, 13, 5164-5175. https://doi.org/10.19102/icrm.2022.130905
|
[28]
|
Jia, R., Ji, Y. and Sun, D. (2022) Progress and Prospects of Sacu-bitril/Valsartan: Based on Heart Failure with Preserved Ejection Fraction. Biomedicine & Pharmacotherapy, 155, Article ID: 113701.
https://doi.org/10.1016/j.biopha.2022.113701
|
[29]
|
Solomon, S.D., et al. (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 381, 1609-1620. https://doi.org/10.1056/NEJMoa1908655
|
[30]
|
Packer, M., et al. (2021) Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circu-lation, 144, 1284-1294.
https://doi.org/10.1161/CIRCULATIONAHA.121.056824
|
[31]
|
詹成创, 王红. 钠-葡萄糖共转运蛋白2抑制剂与心房颤动关系的研究进展[J]. 中国循环杂志, 2022, 37(8): 860-864.
|
[32]
|
Sugumar, H., et al. (2021) A Prospective Study Using Invasive Haemodynamic Measurements Following Catheter Ablation for Af and Early HFpEF: STALL AF-HFpEF. European Journal of Heart Failure, 23, 785-796.
https://doi.org/10.1002/ejhf.2122
|
[33]
|
Rattka, M., et al. (2021) Catheter Ablation for Atrial Fibrillation in HFpEF Patients—A Propensity-Score-Matched Analysis. Journal of Cardiovascular Electrophysiology, 32, 2357-2367. https://doi.org/10.1111/jce.15200
|
[34]
|
Gerdes, A.M., et al. (2021) Ignoring a Basic Pathophysiological Mechanism of Heart Failure Progression Will Not Make It Go away. American Journal of Physiology-Heart and Circulatory Physi-ology, 320, H1919-H1922.
https://doi.org/10.1152/ajpheart.00105.2021
|